Environment-mediated drug resistance in AML
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the development of environment-mediated drug resistance in acute myeloid leukemia (AML) and highlights the importance of understanding the implications of the microenvironment in resistance to therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
